{"entity":{"id":"paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024","kind":"paper","name":"Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma","aka":[],"tldr":"In osteosarcoma, a personalised blood test for leftover cancer after surgery predicted who would relapse, sometimes months before scans.","summary":"Of 83 patients with osteosarcoma at the First Affiliated Hospital of Sun Yat-sen University, tumour-informed panels from whole-exome sequencing were obtained for 71 (85.5 per cent); 59 had panels and blood samples. Thirteen had ctDNA detected after surgery. Negative postoperative ctDNA was associated with better event-free survival at each time point studied and was a significant predictor in multivariate analysis; ctDNA preceded positive imaging in five patients by an average of 92.6 days.","asOf":"2026-11-04","links":[{"label":"Fu et al., eClinicalMedicine 2024","url":"https://doi.org/10.1016/j.eclinm.2024.102697"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/39022798/"}],"tags":[],"related":[],"cancers":["osteosarcoma"],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":["orimiracle-s"],"companies":["origimed"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"eClinicalMedicine","year":2024,"doi":"10.1016/j.eclinm.2024.102697","pmid":"39022798","authors":"Fu Y, Xu Y, Liu W, et al.","paperType":"observational","findings":["Panels obtained for 85.5% of patients.","13 of 59 ctDNA-positive after surgery; ctDNA predicted event-free survival.","Lead time over imaging 92.6 days on average in 5 patients."],"whatItMeans":"Residual disease blood tests extend to bone sarcoma. The methods state a variant allele frequency limit of 0.01 per cent.","caveats":["Single centre."],"participants":59},"route":"/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"orimiracle-s","kind":"drug","name":"OriMIRACLE S","route":"/drugs/orimiracle-s/"}],"company":[{"id":"origimed","kind":"company","name":"OrigiMed","route":"/companies/origimed/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}